BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24615009)

  • 1. TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia.
    Dong HJ; Fang C; Wang L; Fan L; Xu J; Wu JZ; Lu TX; Li JY; Xu W
    Med Oncol; 2014 Apr; 31(4):908. PubMed ID: 24615009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population.
    Mohammed Basabaeen AA; Abdelgader EA; Babekir EA; Abdelrahim SO; Eltayeb NH; Altayeb OA; Fadul EA; Sabo A; Ibrahim IK
    Asian Pac J Cancer Prev; 2019 May; 20(5):1579-1585. PubMed ID: 31128065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms and haplotypes in multidrug resistance 1 gene are not associated with chronic lymphocytic leukemia susceptibility and prognostic parameters of chronic lymphocytic leukemia in Chinese population.
    Dong HJ; Miao KR; Qiao C; Zhuang Y; Shen WY; Hong M; Fan L; Liu P; Xu W; Li JY
    Leuk Lymphoma; 2011 Jun; 52(6):1003-9. PubMed ID: 21463115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
    Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
    Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
    Gonzalez D; Martinez P; Wade R; Hockley S; Oscier D; Matutes E; Dearden CE; Richards SM; Catovsky D; Morgan GJ
    J Clin Oncol; 2011 Jun; 29(16):2223-9. PubMed ID: 21483000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 codon 72 single nucleotide polymorphism in chronic lymphocytic leukemia.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martіna ZV
    Exp Oncol; 2014 Dec; 36(4):258-61. PubMed ID: 25537220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer.
    Chien WP; Wong RH; Wu TC; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2009 Jul; 16(7):1918-24. PubMed ID: 19434453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.
    Lind H; Ekstrøm PO; Ryberg D; Skaug V; Andreassen T; Stangeland L; Haugen A; Zienolddiny S
    Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2077-81. PubMed ID: 17932356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
    Szymanowska A; Jassem E; Dziadziuszko R; Borg A; Limon J; Kobierska-Gulida G; Rzyman W; Jassem J
    Lung Cancer; 2006 Apr; 52(1):9-14. PubMed ID: 16499995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
    Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
    Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
    Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
    Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.
    Willander K; Ungerbäck J; Karlsson K; Fredrikson M; Söderkvist P; Linderholm M
    Eur J Haematol; 2010 Sep; 85(3):251-6. PubMed ID: 20491880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13).
    Dong HJ; Zhou LT; Zhu DX; Wang DM; Fang C; Zhu HY; Zhuang Y; Miao KR; Xu W; Li JY
    Ann Hematol; 2011 Jun; 90(6):709-17. PubMed ID: 21113594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage.
    Malcikova J; Smardova J; Rocnova L; Tichy B; Kuglik P; Vranova V; Cejkova S; Svitakova M; Skuhrova Francova H; Brychtova Y; Doubek M; Brejcha M; Klabusay M; Mayer J; Pospisilova S; Trbusek M
    Blood; 2009 Dec; 114(26):5307-14. PubMed ID: 19850740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Most morphologic features in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status.
    Garcia CF; Hunt KE; Kang H; Babb A; Gale JM; Vasef MA; Reichard KK
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):119-27. PubMed ID: 19826250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance of TP53 for CLL diagnostics.
    Catherwood MA; Gonzalez D; Donaldson D; Clifford R; Mills K; Thornton P
    J Clin Pathol; 2019 May; 72(5):343-346. PubMed ID: 30712002
    [No Abstract]   [Full Text] [Related]  

  • 19. LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations.
    Kristensen L; Kristensen T; Abildgaard N; Royo C; Frederiksen M; Mourits-Andersen T; Campo E; Møller MB
    Eur J Haematol; 2016 Aug; 97(2):175-82. PubMed ID: 26558352
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Bomben R; Rossi FM; Vit F; Bittolo T; D'Agaro T; Zucchetto A; Tissino E; Pozzo F; Vendramini E; Degan M; Zaina E; Cattarossi I; Varaschin P; Nanni P; Berton M; Braida A; Polesel J; Cohen JA; Santinelli E; Biagi A; Gentile M; Morabito F; Fronza G; Pozzato G; D'Arena G; Olivieri J; Bulian P; Pepper C; Hockaday A; Schuh A; Hillmen P; Rossi D; Chiarenza A; Zaja F; Di Raimondo F; Del Poeta G; Gattei V
    Clin Cancer Res; 2021 Oct; 27(20):5566-5575. PubMed ID: 34285062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.